These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 24440304)

  • 1. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists.
    Irani J
    Eur Urol; 2015 Aug; 68(2):339. PubMed ID: 26149730
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
    Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
    J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
    Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
    BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
    Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
    Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
    Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.